早期急性T细胞介导排斥反应与肾移植结局
该多中心观察性队列纳入2013至2019年间5762例成人肾移植受者,共9780次活检,13.6%发生TCMR。36%患者临床恶化,32%随访活检持续TCMR;持续TCMR与移植物丢失风险显著升高独立相关(HR 3.21,95%CI 2.19-4.71),挑战TCMR临床良性观念。
要点
- 早期TCMR常见且常治疗抵抗,36%临床恶化、32%活检持续。
- 持续TCMR者移植物丢失风险显著高于治疗反应者(HR 3.21)。
- 临床改善常不反映组织学缓解,需响应导向监测。
核心结论
- TCMR常见且常治疗抵抗,持续TCMR与长期移植物存活不良强相关。
- 临床改善常不反映组织学反应,持续炎症是移植物丢失的关键驱动因素。
研究设计与样本
- 共5762例患者、9780次活检,评估移植后第一年TCMR发生率及治疗反应与长期结局关联。
主要发现
- 790例(13.6%)发生TCMR;尽管治疗,36%临床恶化,32%随访活检持续TCMR。
- 临床与组织学反应常不一致:临床改善者仅51%无排斥,临床恶化者37%也无排斥。
- TCMR与更差移植物存活显著相关(死亡删失移植物丢失HR 2.84,95%CI 2.38-3.3)。
- 持续TCMR较治疗反应性TCMR移植物丢失风险更高(HR 3.21,95%CI 2.19-4.71),独立于临床反应和混杂因素。
- 肾小管间质炎症(Banff Δ‘t+i’评分)与不良结局呈分级关联,持续或复发性炎症与移植物丢失逐步增加。
关键数值与推荐
- TCMR发生率13.6%(790/5762)。
- 持续TCMR定义基于随访活检持续存在TCMR。
- 移植物丢失风险:TCMR总体HR 2.84(95%CI 2.38-3.3);持续TCMR vs 反应性TCMR HR 3.21(95%CI 2.19-4.71)。
临床怎么用
- 不应将早期TCMR视为临床良性,需重视治疗抵抗和持续炎症。
- 临床改善不能替代组织学评估,建议响应导向的监测策略。
- 持续TCMR患者需更有效靶向治疗以改善长期移植物存活。
局限性
- 观察性队列研究,可能存在残余混杂。
- 原文未报告具体治疗方案的标准化细节。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
INTRODUCTION: Despite the prevalent notion that early acute T cell-mediated rejection (TCMR) in kidney transplant patients is clinically benign, how it responds to treatment and whether treatment responses impact long-term graft survival remain unclear and poorly characterized. METHODS: To comprehensively address this issue, we conducted an observational cohort study of all adult patients who underwent kidney transplantation between January 2013 and December 2019 across six centers in the United States and Europe. We evaluated the incidence of TCMR in the first post-transplant year, assessed clinical and histological responses to treatment, and examined their association with long-term graft outcomes. RESULTS: Among 5,762 patients undergoing 9,780 biopsies, 790 (13.6%) developed TCMR. Despite treatment, 36% of patients demonstrated clinical deterioration and 32% had persistent TCMR on follow-up biopsy, indicating frequent treatment resistance. Clinical and histologic responses were frequently discordant. While only 51% of patients with clinical improvement had no rejection, 37% with clinical deterioration also showed no rejection. TCMR was significantly associated with worse graft survival (death-censored graft loss hazard ratio 2.84, 95% confidence interval 2.38-3.3). Importantly, persistent TCMR conferred a substantially higher risk of graft loss compared with responsive TCMR (3.21, 2.19-4.71) independent of clinical response and other confounders. This association was consistent across subgroups and supported by time-dependent and landmark analyses. Increasing tubulointerstitial inflammation (Banff Δ 't+i' scores) demonstrated a graded association with adverse outcomes, and trajectory analyses showed a stepwise increase in graft loss with persistent or recurrent inflammation. CONCLUSIONS: TCMR is common, frequently treatment-resistant, and persistent TCMR is strongly associated with inferior long-term graft survival. Clinical improvement often failed to reflect histologic response. These findings challenge the notion that TCMR is clinically benign and identify persistent inflammation as a key driver of graft loss, underscoring the need for response guided monitoring and more effective targeted therapies.
引用
- Chen C, Elias C, Keyser M, et al. Early acute T cell-mediated rejection and kidney allograft outcomes. Kidney Int. 2026. PMID: 42508609. doi:10.1016/j.kint.2026.06.042
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。